Romosozumab Tops Teriparatide in Phase 3 Osteoporosis Study Romosozumab Tops Teriparatide in Phase 3 Osteoporosis Study

Romosozumab, a novel investigational agent that both promotes bone formation and inhibits bone resorption, showed positive results at the hip and spine at 1 year. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news